|
AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines. The Cambridge-based pharmaceutical company said enrolment timeline and low event rates made it prohibitive to deliver study results within a timeframe to meaningfully advance clinical practice. They are part of the Crystalize evidence programme, which researches the benefit of Lokelma in the management of hyperkalaemia across the cardiorenal spectrum. Hyperkalaemia describes serum or plasma potassium level above the upper limits of a healthy range, which can cause muscle weakness, paralysis and life-threatening cardiac arrhythmia. Cardiac arrhythmia is an abnormal heartbeat. AstraZeneca shares rose 0.7% to 10,204.00 pence each on Friday morning in London. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
